logo
Commentary: China's defence industry is getting a DeepSeek moment with India-Pakistan clash

Commentary: China's defence industry is getting a DeepSeek moment with India-Pakistan clash

CNA15-05-2025

HONG KONG: In investing, narratives can matter a lot more than earnings or cash flow analysis.
Pakistan is certainly spinning a good story about China's defence industry. Its army said it used Chinese J-10C planes to shoot down five Indian jets, including three Rafales, a MIG-29 and a Su-30. Rafales are made by France's Dassault Aviation, while the other two were imported from Russia. India's government has not confirmed or denied Islamabad's claim and evidence remains inconclusive.
Nonetheless, investors got excited. It was the first real combat between modern Chinese warplanes and advanced Western jets – and surprisingly, China seems to have come out on top. On Monday (May 12), Avic Chengdu Aircraft, which made the J-10C jets, soared 20.6 per cent, while Dassault tumbled 6.2 per cent.
Some are hailing it as another DeepSeek moment for China. In late January, a little-known Hangzhou-based startup released an AI reasoning model that performed almost as well as OpenAI at a fraction of the cost, thereby propelling a bull run in Chinese tech names.
Are we witnessing a repeat, in defence this time?
GLOBAL ARMS EXPORT
I see parallels. While the jury is still out on how disruptive DeepSeek is to US big tech, its arrival has pointed to a new way forward for China, and shows that growth is still possible despite US President Donald Trump's tariffs.
More than manufacturing electronics and apparel, Chinese companies can be good at making software, too, the thinking goes. Over time, they might just be able to gain market share in services exports, which the US dominates.
Similarly, Chinese defence companies might one day be able to sell more weapons overseas.
Between 2020 and 2024, China accounted for only 5.9 per cent of global arms exports, well behind America's 43 per cent, according to the Stockholm International Peace Research Institute. In addition, there's little geographical diversity; almost two-thirds of China's weapons exports went to Pakistan.
So imagine China selling more warplanes and missiles to the Global South. Already, it's the biggest supplier in West Africa, accounting for 26 per cent of total arms imports there. This is lucrative business: Dassault Aviation notched 17 per cent net income margin last year.
MARKETING MILITARY MIGHT
To be sure, investors will have to wait for months, if not years, to see if developing nations friendly with Beijing will place more military equipment orders. But positioning well ahead of positive earnings is nothing new.
German and French defence names are on fire this year, triggered by the White House's isolationist foreign policies and NATO countries' vows to ramp up spending. Whether the Europeans can get their act together is another matter.
But that has not stopped Dassault from rallying more than 50 per cent for the year despite Monday's drop. Meanwhile, Germany's Rheinmetall and Hensoldt more than doubled in market value.
There is also the lack of availability. One reason European military stocks are doing so well is because there are only a handful of publicly listed names that asset managers can get exposure to. After all, for decades Europe relied on the US for national security, so the continent's defence industry is fragmented and in need of an overhaul.
A similar picture emerged in China. Military modernisation is new and the country only weaned itself off imported Russian weapons in the mid-2010s.
For arms exporters, there's no better advertisement success in a real confrontation. In a way, China's long-held friendship with Pakistan is already paying off. Islamabad is doing a great job marketing Beijing's military might.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hong Kong's New World Development gets US$11.24 billion refinancing
Hong Kong's New World Development gets US$11.24 billion refinancing

CNA

timean hour ago

  • CNA

Hong Kong's New World Development gets US$11.24 billion refinancing

Hong Kong builder New World Development said on Monday (Jun 30) it had received commitments for a HK$88.2 billion (US$11.24 billion) loan refinancing, as the builder finalises a crucial lifeline in a distressed property market. New World's refinancing, poised to be one of the largest ever seen in Hong Kong, concludes months of negotiations over a debt package designed to steer the company away from the brink of default. The deal offers a temporary reprieve, while China's prolonged property downturn continues to cast a shadow over the developer's outlook. New World said it had refinanced portions of its existing offshore unsecured debt, including bank loans, through a new facility, and had also aligned the terms of its remaining loan agreements. The new facility consists of multiple tranches of bank loans with different maturities, with the earliest being Jun 30, 2028. The refinancing includes terms such as financial covenants and security over certain assets that provide the firm with greater flexibility to effectively manage its ongoing business operations and financial requirements, the company said. 'We would like to express our sincere gratitude to the banking community for their continued support. This is a testament to the confidence placed in our operation,' said Echo Huang, CEO of New World. She added that the Group's financial management strategy is to prioritise reducing indebtedness and improving cash flow.

US-based I Squared Capital dumps plans to make separate offer for Hong Kong's HKBN
US-based I Squared Capital dumps plans to make separate offer for Hong Kong's HKBN

Business Times

timean hour ago

  • Business Times

US-based I Squared Capital dumps plans to make separate offer for Hong Kong's HKBN

[HONG KONG] US-based infrastructure investment firm I Squared Capital has withdrawn plans to make a takeover offer for Hong Kong's HKBN, the broadband operator said on Monday (Jun 30), as a competing bid backed by a state-owned entity takes centre stage. The announcement comes over a month after Reuters reported that China Mobile was nearing a deal to take over HKBN with I Squared having dropped out. I Squared already owns Hong Kong-based broadband provider HGC Global Communications, in which China Investment Corp holds a minority stake. However, the Miami-based firm has so far been unable to secure approval from the Chinese sovereign wealth fund to proceed with a formal bid for HKBN, according to the Reuters report. Rival suitor China Mobile built a 15.5 per cent stake in HKBN from buyout company TPG and has offered HK$7.8 billion (S$1.3 billion) for the broadband firm. I Squared was preparing to trump China Mobile's offer of HK$5.23 per HKBN share, which was made in December, but was not keen to pay more than HK$6 apiece, Reuters reported in January. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up HKBN CEO William Yeung said in May it was a 'rumour' that China Investment Corp had vetoed I Squared's plan to present a formal offer for HKBN. The takeover offer from China Mobile was not good enough and HKBN was open to engage with more bidders to get the best value for its shareholders, Yeung had said. 'Despite the HKBN CEO's comments that the China Mobile offer is not good enough, China Mobile has no pressing need to bump if a competing offer fails to materialise,' Smartkarma's Arun George said in a note before HKBN's announcement on Monday. I Squared Capital did not immediately respond to Reuters' request for comment over why it decided to walk away from making an offer. China Mobile also did not respond to a request for comment. REUTERS

Hong Kong's China Medical System Holdings plans SGX secondary listing
Hong Kong's China Medical System Holdings plans SGX secondary listing

Independent Singapore

timean hour ago

  • Independent Singapore

Hong Kong's China Medical System Holdings plans SGX secondary listing

SINGAPORE: Hong Kong-listed China Medical System Holdings (CMS) plans a secondary listing on the Mainboard of the Singapore Exchange (SGX), with shares set to trade in July 2025. This is part of its regional expansion strategy to tap investors in the city-state and expand in Southeast Asia's fast-growing healthcare market. The secondary listing is expected to raise its profile and tap a pool of sophisticated healthcare and life sciences investors. The firm has already secured a letter of eligibility from the Singapore bourse. China Medical System is part of the Hang Seng Large-Mid Cap (Investable) Index. Since 2023, it's also been part of the Hang Seng Innovative Drug Index. This is due to its evolving focus on cutting-edge therapies. The last two years have been challenging for the company due to the impact of Beijing's stand on volume-based procurement (VBP) policy. Designed to reduce the cost of drugs and medical devices, the VBP scheme has driven steep price competition, affecting firms with more traditional product lines. This led CMS to transition to an innovation-led business model that focuses on high-value, clinically driven products. According to company reports, it's in gradual recovery from the effects of VBP. It predicts renewed growth momentum, with a pipeline of approximately 40 innovative projects as of the end of 2024. With a regional population close to 700 million, Southeast Asia's growing demand for medicine is fuelled by a mix of factors. This includes a growing regional middle class, the spread of lifestyle diseases, and ageing demographics in countries like Singapore and Thailand. CMS will tap this market through two entities. The first is Singapore-based Rxilient Health, a regional unit focused on global licensing and commercialisation of pharmaceuticals. The second is CMS's associated firm, PharmaGend Global, which has acquired a Singapore-based contract development and manufacturing organisation (CDMO). This facility spans over 60,000 square metres and can produce up to 1 billion tablets and capsules annually. Rxilient Health has operations in Malaysia, Vietnam, Indonesia, the Philippines, and Thailand. This will enable market localisation, while commercial production in Singapore, which began at the end of 2024, will enable supply to regional customers. The Singapore facility has received a Good Manufacturing Practice certification from the US Food and Drug Administration (FDA) and passed inspections by Singapore's Health Sciences Authority (HSA). FY2024 saw China Medical System face significant financial challenges. Its earnings dropped by 32.5% compared to the previous year, falling to RMB 1.62 billion (~US$288 million or S$367 million). This also saw a decline in gross profit (11.2%) as well as net profit (32.3%). The company is banking on its investments in innovation and overseas market expansion to drive future recovery and growth. The timing of the secondary listing comes amid strong momentum on the Singapore bourse. SGX shares rose 7.2% last week, hitting a five-year high of S$14.72 on Jun 27. The Straits Times Index (STI) closed the week at 3,966.20, up 0.7%. Investors appear to be leaning on Singapore's stability as global concerns over inflation, oil prices, and tariffs continue. Trading activity has picked up noticeably, especially in the small and mid-cap segments.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store